Exploring death receptor pathways as selective targets in cancer therapy
Maria Russo1, Annalisa Mupo, Carmela Spagnuolo
1Institute of Food Sciences, National Research Council, 83100 Avellino, Italy.
Biochemical Pharmacology
|March 23, 2010
Summary
Activating cancer cell apoptosis via death receptors (DRs) shows promise. Further research is needed to ensure DR-based therapies are selective, effective, and overcome resistance mechanisms for safe clinical use.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Death receptors (DRs) like TNF, CD95, and TRAIL are key targets in cancer therapy.
- DR activation aims to induce apoptosis specifically in tumor cells.
- Current clinical trials show therapeutic potential for DR agonistic antibodies and proteins.
Purpose of the Study:
- To review new insights into the signaling pathways of TNF, CD95, and TRAIL receptors.
- To discuss the clinical applications of DR-based cancer therapies.
- To address challenges in DR-based cancer therapy, including selectivity, toxicity, and resistance.
Main Methods:
- Review of existing literature on DR signaling and cancer therapy.
- Analysis of clinical trial data for DR-targeting agents.
- Exploration of alternative signaling pathways that promote cell survival and resistance.
Main Results:
- DR-based therapies show promise but require further investigation.
- Tumor resistance and systemic toxicity are significant challenges.
- Alternative signaling pathways (e.g., NF-kappaB, JNK, p38, ERK, PI(3)K) can mediate survival and apoptotic resistance.
Conclusions:
- DR-based cancer therapy holds significant therapeutic potential.
- Overcoming tumor resistance and minimizing systemic toxicity are critical for clinical success.
- A deeper understanding of DR signaling, including pro-survival pathways, is essential for developing effective and safe treatments.
More Related Videos
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:17The Extrinsic Apoptotic Pathway
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:26Protein Networks
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...